

N S Oliver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8868505/publications.pdf>

Version: 2024-02-01

162
papers

4,793
citations

156536

32
h-index

124990

64
g-index

167
all docs

167
docs citations

167
times ranked

7022
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards targeted dietary support for shift workers with type 2 diabetes (Shiftâ€”Diabetes study): A mixedâ€”methods case study protocol. <i>Diabetic Medicine</i> , 2022, 39, e14714.	1.2	2
2	Preserved C-peptide in survivors of COVIDâ€”19: Post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 570-574.	2.2	8
3	Identifying Continuous Glucose Monitoring Data Using Machine Learning. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 403-408.	2.4	5
4	Variance of concern. <i>Diabetic Medicine</i> , 2022, 39, e14782.	1.2	0
5	Identifying the outcomes important to men with hypogonadism: A qualitative evidence synthesis. <i>Andrology</i> , 2022, , .	1.9	4
6	A game for all shapes and sizes? Changes in anthropometric and performance measures of elite professional rugby union players 1999â€”2018. <i>BMJ Open Sport and Exercise Medicine</i> , 2022, 8, e001235.	1.4	3
7	Taking back control. <i>Diabetic Medicine</i> , 2022, 39, e14802.	1.2	0
8	Diagnostic challenge. <i>Diabetic Medicine</i> , 2022, 39, e14823.	1.2	0
9	Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: A systematic review and metaâ€”analysis of randomised controlled trials. <i>Diabetic Medicine</i> , 2022, 39, e14854.	1.2	44
10	Itâ€™s complicated. <i>Diabetic Medicine</i> , 2022, 39, e14867.	1.2	0
11	Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 749-753.	2.4	10
12	The impact of socioâ€”economic deprivation on access to diabetes technology in adults with type 1 diabetes. <i>Diabetic Medicine</i> , 2022, 39, .	1.2	15
13	Enhancing self-management in type 1 diabetes with wearables and deep learning. <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	23
14	Diabetes selfâ€”management during the COVIDâ€”19 pandemic and its associations with COVIDâ€”19 anxiety syndrome, depression and health anxiety. <i>Diabetic Medicine</i> , 2022, 39, .	1.2	5
15	Safety and Feasibility of the PEPPER Adaptive Bolus Advisor and Safety System: A Randomized Control Study. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 175-186.	2.4	20
16	Robust Determination of the Optimal Continuous Glucose Monitoring Length of Intervention to Evaluate Long-Term Glycemic Control. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 314-319.	2.4	32
17	Evaluation of the Accuracy of Current Tubeless Pumps for Continuous Subcutaneous Insulin Infusion. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 350-357.	2.4	9
18	Taking measure. <i>Diabetic Medicine</i> , 2021, 38, e14510.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. <i>Diabetologia</i> , 2021, 64, 935-938.	2.9	4
20	Increased Mortality Risk in Patients With Primary and Secondary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2759-e2768.	1.8	34
21	A complex archetype. <i>Diabetic Medicine</i> , 2021, 38, e14533.	1.2	0
22	Cardiovascular Disease in Patients With Primary and Secondary Adrenal Insufficiency and the Role of Comorbidities. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1284-1293.	1.8	11
23	Best foot forward. <i>Diabetic Medicine</i> , 2021, 38, e14550.	1.2	0
24	Holding steady. <i>Diabetic Medicine</i> , 2021, 38, e14579.	1.2	0
25	Changes. <i>Diabetic Medicine</i> , 2021, 38, e14593.	1.2	0
26	Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2242-2251.	1.8	6
27	Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring: A Follow-Up Analysis Using Real-Life Data. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 392-396.	2.4	5
28	Increasing glycaemia is associated with a significant decline in HDL cholesterol in women with prediabetes in two national populations. <i>Scientific Reports</i> , 2021, 11, 12194.	1.6	3
29	Outside in. <i>Diabetic Medicine</i> , 2021, 38, e14615.	1.2	0
30	Improved glycaemia during the Covid-19 pandemic lockdown is sustained post-lockdown and during the "Eat Out to Help Out" Government Scheme, in adults with Type 1 diabetes in the United Kingdom. <i>PLoS ONE</i> , 2021, 16, e0254951.	1.1	3
31	DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life. <i>Diabetologia</i> , 2021, 64, 2258-2265.	2.9	8
32	People power. <i>Diabetic Medicine</i> , 2021, 38, e14619.	1.2	0
33	August Editorial "People Power"™. <i>Diabetic Medicine</i> , 2021, , e14633.	1.2	0
34	Automated Insulin Delivery Systems: Today, Tomorrow and User Requirements. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 193229682110299.	1.3	3
35	Cross-sectional analysis of emergency hypoglycaemia and outcome predictors among people with diabetes in an urban population. <i>Diabetic Medicine</i> , 2021, 38, e14654.	1.2	1
36	Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or sensor first? A meta-analysis using pooled differences in outcome measures. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2521-2528.	2.2	9

#	ARTICLE	IF	CITATIONS
37	Focussing care. <i>Diabetic Medicine</i> , 2021, 38, e14667.	1.2	0
38	The power of equality. <i>Diabetic Medicine</i> , 2021, 38, e14709.	1.2	0
39	Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. <i>Diabetes Care</i> , 2021, 44, 614-617.	4.3	9
40	Pregnancy and contraception in women with Pre-Gestational diabetes in secondary Careâ€” A questionnaire study. <i>Diabetes Research and Clinical Practice</i> , 2021, 182, 109124.	1.1	2
41	An In Silico Head-to-Head Comparison of the Do-It-Yourself Artificial Pancreas Loop and Bio-Inspired Artificial Pancreas Control Algorithms. <i>Journal of Diabetes Science and Technology</i> , 2021, , 193229682110600.	1.3	3
42	A Modular Safety System for an Insulin Dose Recommender: A Feasibility Study. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 87-96.	1.3	18
43	Is it possible to constantly and accurately monitor blood sugar levels, in people with Type 1 diabetes, with a discrete device (nonâ€”invasive or invasive)?. <i>Diabetic Medicine</i> , 2020, 37, 532-544.	1.2	30
44	Hyperglycemia recognised in early pregnancy is phenotypically type 2 diabetes mellitus not gestational diabetes mellitus: a case control study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 3977-3983.	0.7	4
45	Predicting Quality of Overnight Glycaemic Control in Type 1 Diabetes Using Binary Classifiers. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 1439-1446.	3.9	29
46	Continuous Glucose Monitoring in People With Type 1 Diabetes on Multiple-Dose Injection Therapy: The Relationship Between Glycemic Control and Hypoglycemia. <i>Diabetes Care</i> , 2020, 43, 53-58.	4.3	18
47	Glycemic Variability and Hypoglycemic Excursions With Continuous Glucose Monitoring Compared to Intermittently Scanned Continuous Glucose Monitoring in Adults With Highest Risk Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 567-574.	1.3	17
48	Differences for Percentage Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 222-227.	2.4	25
49	Self-Monitoring of Blood Glucose Requirements with the Use of Intermittently Scanned Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 235-238.	2.4	5
50	Evolving type 1 diabetes in distinguishing between type 1 and type 2 diabetes. <i>BMJ, The</i> , 2020, 370, m3772.	3.0	0
51	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). <i>Diabetologia</i> , 2020,	2.9	102
52	Glucose management for exercise using continuous glucose monitoring (<scp>CGM</scp>) and intermittently scanned <scp>CGM</scp> (<scp>isCGM</scp>) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (<scp>EASD</scp>) and of the International Society for Pediatric and Adolescent Diabetes (<scp>ISPAD</scp>) endorsed by <scp>. <i>Pediatric Diabetes</i> , 2020, 21, 1375-1393.	1.2	46
53	Response to Comment on Misra et al. Homozygous Hypomorphic HNF1A Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes. <i>Diabetes Care</i> 2020;43:909â€”912. <i>Diabetes Care</i> , 2020, 43, e155-e156.	4.3	0
54	New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.. <i>Diabetes Care</i> , 2020, 43, e170-e171.	4.3	290

#	ARTICLE	IF	CITATIONS
55	Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 577-597.	2.6	45
56	The James Lind Alliance Research Priorities for Diabetes revisited. <i>Diabetic Medicine</i> , 2020, 37, 511-512.	1.2	0
57	Updated Software for Automated Assessment of Glucose Variability and Quality of Glycemic Control in Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 701-708.	2.4	22
58	Assessment of Glucose Control Metrics by Discriminant Ratio. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 719-726.	2.4	22
59	Clinical impact of CGM use. , 2020, , 135-158.		0
60	Response to Letter by Seibold regarding "Glycemic Variability and Hypoglycemic Excursions With Continuous Glucose Monitoring Compared to Intermittently Scanned Continuous Glucose Monitoring in Adults With Highest Risk Type 1 Diabetes" Journal of Diabetes Science and Technology, 2020, 14, 697-698.	1.3	0
61	A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial. <i>Diabetologia</i> , 2020, 63, 486-496.	2.9	38
62	Homozygous Hypomorphic <i>HNF1A</i> Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes. <i>Diabetes Care</i> , 2020, 43, 909-912.	4.3	13
63	Experience of point-of-care HbA1c testing in the English National Health Service Diabetes Prevention Programme: an observational study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, .	1.2	2
64	Individual and diabetes presentation characteristics associated with partial remission status in children and adults evaluated up to 12 months following diagnosis of type 1 diabetes: An ADDRESS-2 (After Diagnosis Diabetes Research Support System-2) study analysis. <i>Diabetes Research and Clinical Practice</i> , 2019, 155, 107789.	1.1	14
65	Long-Term Glucose Forecasting Using a Physiological Model and Deconvolution of the Continuous Glucose Monitoring Signal. <i>Sensors</i> , 2019, 19, 4338.	2.1	22
66	The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary Results. <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 1017-1025.	1.3	9
67	Rationale and protocol for the Assessment of Impact of Real-time Continuous Glucose Monitoring on people presenting with severe Hypoglycaemia (AIR-CGM) study. <i>BMC Endocrine Disorders</i> , 2019, 19, 110.	0.9	4
68	Animal Models of Diabetes-Related Male Hypogonadism. <i>Frontiers in Endocrinology</i> , 2019, 10, 628.	1.5	6
69	Reply to Letter by Seibold regarding Monika Reddy, Narvada Jugnee, Sinthuka Anantharaja, and Nick Oliver, Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 99-100.	2.4	3
70	Metabolic health and vascular complications in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 634-640.	1.2	4
71	Glycemic Index, Extended Bolusing, and Diabetes Education in Insulin Pump Therapy (GLIDE: A Pilot) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	2.4	12
72	Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes. <i>Drugs</i> , 2019, 79, 1089-1101.	4.9	29

#	ARTICLE	IF	CITATIONS
73	Open source automated insulin delivery: addressing the challenge. <i>Npj Digital Medicine</i> , 2019, 2, 124.	5.7	17
74	Cardiometabolic risk factors in Thai individuals with prediabetes treated in a high-risk, prevention clinic: Unexpected relationship between high-density lipoprotein cholesterol and glycemia in men. <i>Journal of Diabetes Investigation</i> , 2019, 10, 771-779.	1.1	1
75	Skinfold thickness measurements and mortality in white males during 27.7 years of follow-up. <i>International Journal of Obesity</i> , 2018, 42, 1939-1945.	1.6	6
76	Automatic Adaptation of Basal Insulin Using Sensor-Augmented Pump Therapy. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 282-294.	1.3	18
77	Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1580.	3.8	313
78	Continuous Glucose Monitoring at High Altitude—Effects on Glucose Homeostasis. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 1679-1686.	0.2	18
79	Intraperitoneal insulin therapy in patients with type 1 diabetes. Does it fit into the current therapeutic arsenal?. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2018, 65, 182-184.	0.1	2
80	Establishing the multidisciplinary Imperial Physical Activity and Diabetes clinic. <i>Practical Diabetes</i> , 2018, 35, 11-15.	0.1	2
81	Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. <i>BMJ Open</i> , 2018, 8, e020904.	0.8	56
82	A pilot study in humans of microneedle sensor arrays for continuous glucose monitoring. <i>Analytical Methods</i> , 2018, 10, 2088-2095.	1.3	89
83	Testosterone therapy for sexual dysfunction in men with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetic Medicine</i> , 2018, 35, 195-202.	1.2	31
84	A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. <i>Diabetic Medicine</i> , 2018, 35, 483-490.	1.2	201
85	Revisiting the Relationships Between Measures of Glycemic Control and Hypoglycemia in Continuous Glucose Monitoring Data Sets. <i>Diabetes Care</i> , 2018, 41, 326-332.	4.3	24
86	Changes in northern hemisphere male international rugby union players' body mass and height between 1955 and 2015. <i>BMJ Open Sport and Exercise Medicine</i> , 2018, 4, e000459.	1.4	20
87	Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 751-757.	2.4	73
88	Protocol for a clinical trial of text messaging in addition to standard care versus standard care alone in prevention of type 2 diabetes through lifestyle modification in India and the UK. <i>BMC Endocrine Disorders</i> , 2018, 18, 63.	0.9	3
89	The post-trial analysis of the Indian SMS diabetes prevention study shows persistent beneficial effects of lifestyle intervention. <i>Diabetes Research and Clinical Practice</i> , 2018, 142, 213-221.	1.1	17
90	Variations in access to and reimbursement for continuous glucose monitoring systems for people living with Type 1 diabetes across England. <i>Diabetic Medicine</i> , 2018, 35, 1617-1618.	1.2	12

#	ARTICLE	IF	CITATIONS
91	Reply to Seibold and Schlaeger: Comparison of continuous and flash glucose monitoring in Type 1 diabetes: methodological inconsistency precludes hypoglycaemia conclusions. <i>Diabetic Medicine</i> , 2018, 35, 1619-1620.	1.2	6
92	A Portable Low-Power Platform for Ambulatory Closed Loop Control of Blood Glucose in Type 1 Diabetes. , 2018, , .		4
93	Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment. <i>Diabetic Medicine</i> , 2018, 35, 1291-1296.	1.2	7
94	Incidence of Type 2 Diabetes is Higher among Men with Persistent Impaired Glucose Tolerance than in Transient Impaired Glucose Tolerance - A 5 year Follow up Study. <i>Journal of the Association of Physicians of India</i> , The, 2018, 66, 22-26.	0.0	0
95	Case-Based Reasoning for Insulin Bolus Advice. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 37-42.	1.3	25
96	Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator “ in silico evaluation under intra-day variability. <i>Computer Methods and Programs in Biomedicine</i> , 2017, 146, 125-131.	2.6	51
97	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 597-609.	5.5	248
98	Managing diabetes at high altitude: personal experience with support from a Multidisciplinary Physical Activity and Diabetes Clinic. <i>BMJ Open Sport and Exercise Medicine</i> , 2017, 3, e000238.	1.4	8
99	Fasting plasma glucose and variation in cardiometabolic risk factors in people with high-risk HbA1c-defined prediabetes: A cross-sectional multiethnic study. <i>Diabetes Research and Clinical Practice</i> , 2017, 134, 183-190.	1.1	1
100	Pharmacological aspects of closed loop insulin delivery for type 1 diabetes. <i>Current Opinion in Pharmacology</i> , 2017, 36, 29-33.	1.7	3
101	Emerging technologies for diabetes. <i>Practical Diabetes</i> , 2017, 34, 240-244.	0.1	0
102	A coordinated control strategy for insulin and glucagon delivery in type 1 diabetes. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2017, 20, 1474-1482.	0.9	24
103	Rationale and protocol for the After Diabetes Diagnosis REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort study. <i>BMJ Open</i> , 2017, 7, e013956.	0.8	8
104	REPOSE: repositioning insulin pump therapy in Type 1 diabetes. <i>Diabetic Medicine</i> , 2017, 34, 1656-1657.	1.2	0
105	Biochemical, Physiological and Psychological Changes During Endurance Exercise in People With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 529-536.	1.3	15
106	Validation and regulation of point of care devices for medical applications. , 2017, , 27-44.		8
107	Continuous Glucose Monitoring Adoption in the United Kingdom “ An Economic and Policy Perspective. <i>European Endocrinology</i> , 2017, 13, 73.	0.8	5
108	An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England. <i>European Endocrinology</i> , 2017, 13, 81.	0.8	9

#	ARTICLE	IF	CITATIONS
109	An Advanced Insulin Bolus Calculator for Type 1 Diabetes. , 2017, , 241-260.		0
110	Clinical Safety and Feasibility of the Advanced Bolus Calculator for Type 1 Diabetes Based on Case-Based Reasoning: A 6-Week Nonrandomized Single-Arm Pilot Study. Diabetes Technology and Therapeutics, 2016, 18, 487-493.	2.4	56
111	South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people. Diabetologia, 2016, 59, 2262-2265.	2.9	28
112	Measures of Glycemic Variability in Type 1 Diabetes and the Effect of Real-Time Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2016, 18, 806-812.	2.4	66
113	Metabolic Control With the Bio-inspired Artificial Pancreas in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 405-413.	1.3	34
114	Live demonstration: Smartwatch implementation of an advanced insulin bolus calculator for diabetes. , 2016, , .		1
115	Gestational diabetes mellitus: does an effective prevention strategy exist?. Nature Reviews Endocrinology, 2016, 12, 533-546.	4.3	82
116	Robust setâ€ membership parameter estimation of the glucose minimal model. International Journal of Adaptive Control and Signal Processing, 2016, 30, 173-185.	2.3	6
117	A Randomised Crossover Trial: The Effect of Inulin on Glucose Homeostasis in Subtypes of Prediabetes. Annals of Nutrition and Metabolism, 2016, 68, 26-34.	1.0	31
118	Type 1 diabetes in adults: supporting self management. BMJ, The, 2016, 352, i998.	3.0	33
119	Glycemic Variability and Its Impact on Quality of Life in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 60-66.	1.3	19
120	An Advanced Bolus Calculator for Type 1 Diabetes: System Architecture and Usability Results. IEEE Journal of Biomedical and Health Informatics, 2016, 20, 11-17.	3.9	45
121	A randomized controlled trial: the effect of inulin on weight management and ectopic fat in subjects with prediabetes. Nutrition and Metabolism, 2015, 12, 36.	1.3	53
122	Is iatrogenic sleep disturbance worth the effort in Type 1 diabetes?. Diabetic Medicine, 2015, 32, 984-986.	1.2	8
123	Response to Rosival: Pathophysiology of diabetic ketoacidosis. Diabetic Medicine, 2015, 32, 1527-1528.	1.2	4
124	Intentional Large Insulin Overdose Captured on a Continuous Glucose Monitor. Journal of Diabetes Science and Technology, 2015, 9, 929-931.	1.3	7
125	Future Artificial Pancreas Technology for Type 1 Diabetes: What Do Users Want?. Diabetes Technology and Therapeutics, 2015, 17, 311-315.	2.4	42
126	Elevated Lactate Levels in Patients With Poorly Regulated Type 1 Diabetes and Glycogenic Hepatopathy: A New Feature of Mauriac Syndrome. Diabetes Care, 2015, 38, e11-e12.	4.3	35

#	ARTICLE	IF	CITATIONS
127	Method for automatic adjustment of an insulin bolus calculator: In silico robustness evaluation under intra-day variability. <i>Computer Methods and Programs in Biomedicine</i> , 2015, 119, 1-8.	2.6	33
128	Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control study. <i>Diabetologia</i> , 2015, 58, 1443-1447.	2.9	67
129	Diabetic ketoacidosis in adults. <i>BMJ, The</i> , 2015, 351, h5660.	3.0	42
130	Psychosocial Assessment of Artificial Pancreas (AP): Commentary and Review of Existing Measures and Their Applicability in AP Research. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 295-300.	2.4	39
131	Technological Advancement in the Treatment of Diabetes—Ignoring Psychosocial Impact at Our Peril. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 149-151.	2.4	6
132	Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices. <i>Diabetes Therapy</i> , 2015, 6, 257-272.	1.2	5
133	Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis. <i>Diabetic Medicine</i> , 2015, 32, 14-23.	1.2	68
134	Comment on Doyle et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. <i>Diabetes Care</i> 2014;37:1191-1197. <i>Diabetes Care</i> , 2014, 37, e226-e227.	4.3	8
135	Live demonstration: A handheld Bio-inspired Artificial pancreas for treatment of diabetes. , 2014, , .		3
136	Advanced Insulin Bolus Advisor based on Run-To-Run Control and Case-Based Reasoning. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2014, 19, 1-1.	3.9	56
137	Live demonstration: An advanced bolus calculator for diabetes management - A clinical and patient platform. , 2014, , .		2
138	Feasibility Study of a Bio-inspired Artificial Pancreas in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 550-557.	2.4	28
139	Use of Microneedle Array Devices for Continuous Glucose Monitoring: A Review. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 101-115.	2.4	108
140	Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel-group, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 191-198.	5.5	262
141	Diabetic ketoacidosis: not always due to type 1 diabetes. <i>BMJ, The</i> , 2013, 346, f3501-f3501.	3.0	29
142	Adiposity Measurements by BMI, Skinfolds and Dual Energy X-Ray Absorptiometry in relation to Risk Markers for Cardiovascular Disease and Diabetes in Adult Males. <i>Disease Markers</i> , 2013, 35, 753-764.	0.6	21
143	A Composite Model of Glucagon-Glucose Dynamics for <i>In Silico</i> Testing of Bihormonal Glucose Controllers. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 941-951.	1.3	45
144	A Bio-Inspired Glucose Controller Based on Pancreatic β -Cell Physiology. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 606-616.	1.3	43

#	ARTICLE	IF	CITATIONS
145	Minimally Invasive Enzyme Microprobes: An Alternative Approach for Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 479-480.	1.3	18
146	A Simple Robust Method for Estimating the Glucose Rate of Appearance from Mixed Meals. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 153-162.	1.3	25
147	Robust Fault Detection System for Insulin Pump Therapy Using Continuous Glucose Monitoring. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1131-1141.	1.3	48
148	Low glycaemic variability in subjects with Type 2 diabetes following pre-Ramadan assessment and adjustments for fasting. <i>Diabetic Medicine</i> , 2012, 29, 828-829.	1.2	2
149	Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 921-928.	2.4	279
150	HbA1c: an old friend in new clothes. <i>Lancet</i> , The, 2011, 377, 1476-1477.	6.3	3
151	HbA1c: what do the numbers really mean? " Authors' reply. <i>Lancet</i> , The, 2011, 378, 1069-1070.	6.3	0
152	VHDL implementation of the Biostator II glucose control algorithm for critical care. , 2011, , .		3
153	An unconscious patient. <i>BMJ: British Medical Journal</i> , 2011, 343, d7266-d7266.	2.4	0
154	A Benchtop Closed-loop System Controlled by a Bio-Inspired Silicon Implementation of the Pancreatic β^2 Cell. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1419-1424.	1.3	7
155	Wireless solutions for managing diabetes: A review and future prospects. <i>Technology and Health Care</i> , 2009, 17, 353-367.	0.5	8
156	Glucose sensors: a review of current and emerging technology. <i>Diabetic Medicine</i> , 2009, 26, 197-210.	1.2	484
157	Conservative management of diabetic forefoot ulceration complicated by underlying osteomyelitis: the benefits of magnetic resonance imaging. <i>Diabetic Medicine</i> , 2009, 26, 1127-1134.	1.2	51
158	A bio-inspired closed-loop insulin delivery based on the silicon pancreatic beta-cell. , 2008, , .		3
159	The role of the biochemistry department in the diagnosis of pituitary apoplexy. <i>Annals of Clinical Biochemistry</i> , 2004, 41, 162-165.	0.8	4
160	An unusual electrocardiographic abnormality. <i>Postgraduate Medical Journal</i> , 2003, 79, 539-540.	0.9	1
161	The Absence of Islet Autoantibodies in Clinically Diagnosed Older-Adult Onset Type 1 Diabetes Suggests an Alternative Pathology, Advocating for Routine Testing in This Age Group. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
162	Mobile Solutions for Managing Health Care. , 0, , 150-171.		0